Ask AI

Decoding Discoveries in Hematologic Malignancies—Decera Clinical Education's Independent Highlights of the 2026 ASCO and EHA Conferences

Text Module
Text Module Start Activity
This activity is available for 1.00 CME/CE credit(s).

Released: August 31, 2026

Expiration: February 28, 2027

See Activity Collection

In this module, 2 world-renowned experts review promising and practice-changing data in studies of hematologic malignancies presented at the 2026 ASCO and EHA conferences. This activity features expert insights and clinical implications of new, novel and emerging strategies in chronic myeloid leukemia, acute myeloid leukemia, myelodysplastic syndromes, myelofibrosis, diffuse large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and follicular lymphoma including latest data from ASC4FIRST (asciminib), MAXILUS (luspatercept), EPO-PRETAR (erythropoietin stimulating agents), OPTI-AML (azacitidine/venetoclax optimization), KOMET-007 (ziftomenib), AJX-101 (AJ1-11095), SENTRY (selinexor/ruxolitinib), frontMIND (tafasitamab/lenalidomide + R-CHOP), BRUIN CLL-322 (pirtobrutinib + venetoclax/rituximab), BRUIN CLL-313/314 (pirtobrutinib), CLL14 (venetoclax/obinutuzumab), CaDAnCe-101 (tacabrutideg), and a sonrotoclax plus zanubrutinib trial.

Hematologic Malignancies From 2026 ASCO and EHA

Pre Assessment

Assess your current knowledge and clinical approach before beginning your text module.
1.

How many people with hematologic malignancies do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

At the 2026 ASCO and EHA meetings, long-term efficacy and safety results from the phase III ASC4FIRST study of oral asciminib vs investigator-selected tyrosine kinase inhibitor (IS-TKI) (imatinib, nilotinib, dasatinib, or bosutinib) for patients with newly diagnosed Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML) in chronic phase (CP) were presented. In your treatment follow-up discussion with your patient with CML-CP who is currently receiving treatment with asciminib, which of the following results would you tell him or her was reported in this analysis?

4.

At EHA 2026, preliminary results from the phase I AJX-101 trial of the novel type II JAK2 inhibitor AJ1-11095 in patients with primary MF, post–polycythemia vera MF, or post–essential thrombocythemia MF were presented. Which of the following results were demonstrated with AJ1-11095?

5.

Which of the following findings would you tell a patient with chronic lymphocytic leukemia (CLL) and progression on a frontline covalent BTK inhibitor was reported from the BRUIN CLL-322 trial of fixed-duration therapy with pirtobrutinib plus venetoclax and rituximab (PVR) vs venetoclax plus rituximab (VR) in patients with relapsed/refractory (R/R) CLL?

6.

A 67-year-old patient with newly diagnosed germinal center B-cell–like (GCB) subtype of diffuse large B-cell lymphoma (DLBCL) and an International Prognostic Index (IPI) score of 4 who was referred to you asks about available evidence regarding the most effective treatment option for him.

Based on the available data from phase III trials, which of the following regimens that have been evaluated as frontline therapy would you tell this patient demonstrated a benefit in PFS for patients with his disease subtype?